The goal of this study was to assess the extent of symmetric arginine dimethylation-dependent splicing and its associated signaling outcomes by using human T lymphocyte activation as a model system with a high rate of de novo transcription. Nave human T lymphocytes were activated and treated with a selective inhibitor of PRMT5, PF-06829927, and investigated for changes in gene expression, alternative splicing, and chromatin accessibility.;	 SOURCE: Patrick,J,Metz Pfizer, Oncology Research, Development, & Medical

Pluto Bioinformatics

GSE141645: Symmetric arginine dimethylation is selectively required for mRNA splicing and the initiation of type I and type III interferon signaling